Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
- Revenue in USD (TTM)30.83bn
- Net income in USD726.30m
- Incorporated1925
- Employees47.46k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 2.35bn | -269.70m | 42.34bn | 2.23k | -- | 366.53 | -- | 18.03 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Takeda Pharmaceutical Co Ltd (ADR) | 30.83bn | 726.30m | 47.47bn | 47.46k | 65.55 | 0.994 | 8.11 | 1.54 | 0.2249 | 0.2249 | 9.69 | 14.83 | 0.3121 | 1.30 | 7.25 | 649,698.30 | 0.7367 | 1.71 | 0.8815 | 2.04 | 65.51 | 67.66 | 2.36 | 5.99 | 0.5202 | 2.52 | 0.3943 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | -- |
| Regeneron Pharmaceuticals Inc | 14.09bn | 4.50bn | 59.38bn | 15.11k | 14.00 | 2.03 | 11.89 | 4.22 | 39.30 | 39.30 | 123.45 | 271.60 | 0.3917 | 0.6347 | 2.61 | 932,457.30 | 12.51 | 18.52 | 13.89 | 21.13 | 86.69 | 87.22 | 31.94 | 37.92 | 4.03 | -- | 0.0843 | -- | 8.27 | 12.55 | 11.61 | 15.84 | 15.46 | -- |
| Zoetis Inc | 9.29bn | 2.52bn | 66.79bn | 13.80k | 26.94 | 14.38 | 22.13 | 7.19 | 5.57 | 5.57 | 20.54 | 10.44 | 0.6529 | 1.07 | 7.00 | 672,898.60 | 17.77 | 15.25 | 21.83 | 18.31 | 70.98 | 70.18 | 27.22 | 26.32 | 1.04 | 21.14 | 0.5856 | 28.93 | 8.33 | 8.14 | 6.06 | 10.63 | 7.32 | 21.37 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 13.20m | 0.42% |
| Parametric Portfolio Associates LLCas of 31 Mar 2025 | 5.29m | 0.17% |
| Strategic Advisers LLCas of 31 Mar 2025 | 3.57m | 0.11% |
| Brandes Investment Partners LPas of 31 Mar 2025 | 3.50m | 0.11% |
| Adage Capital Management LPas of 31 Mar 2025 | 3.43m | 0.11% |
| Renaissance Technologies LLCas of 31 Mar 2025 | 3.16m | 0.10% |
| Goldman Sachs Asset Management LPas of 31 Mar 2025 | 2.89m | 0.09% |
| First Trust Advisors LPas of 31 Mar 2025 | 2.76m | 0.09% |
| Aperio Group LLCas of 31 Mar 2025 | 2.63m | 0.08% |
| Van Eck Associates Corp.as of 31 Mar 2025 | 2.17m | 0.07% |
